Fig. 4.

EGFR variant III rescues oncogene addiction. (A) Schematic of full-length EGFR and EGFR vIII. (B) PC9 cells stably expressing the indicated cDNAs were treated with the shEGFR vector and analyzed as in Fig. 2 C. (C) Lysates were examined by immunoblotting with the indicated antibodies after transduction of cells as in Fig. 2 B. As expected, exogenous EGFR vIII migrates with faster mobility than the endogenous full-length protein.